Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1433660

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1433660

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product Type (Semi-Solid, Liquid), By Service Type (Contract Development, Contract Manufacturing), By Sponsors, By Country, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 26.45 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 65.0% share in 2023, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2023. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products
Product Code: GVR-4-68040-188-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in the U.S.
    • 1.5.2. Data for primary interviews in Canada
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. North America Topical Drugs CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Pricing Analysis
  • 3.5. Topical Drugs CDMO Capacity Outlook
    • 3.5.1. CDMO Manufacturing Container Capacity
    • 3.5.2. Topical Drugs Container Capacity By Product Type
  • 3.6. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.6.1. North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
    • 3.6.2. Prescription Drugs
      • 3.6.2.1. Segment Overview
      • 3.6.2.2. Major Prescription Drugs, By Product Type
    • 3.6.3. Generic Drugs
      • 3.6.3.1. Segment Overview
      • 3.6.3.2. Major Generic Drugs, By Product Type
    • 3.6.4. Over-the-counter (OTC) Drugs
      • 3.6.4.1. Segment Overview
      • 3.6.4.2. Major OTC Drugs, By Product Type
  • 3.7. Impact of COVID-19 Pandemic

Chapter 4. North America Topical Drugs CDMO Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Type Estimates & Trend Analysis

  • 5.1. Service Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: Sponsors Estimates & Trend Analysis

  • 6.1. Sponsors Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by Sponsors Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2023 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework
    • 7.5.3. Competitive scenario
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Regulatory framework
    • 7.6.3. Competitive scenario
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. The Lubrizol Corporation
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product/service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Cambrex Corporation
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product/service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Contract Pharmaceuticals Limited
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product/service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bora Pharmaceutical CDMO
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product/service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Ascendia Pharmaceuticals
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product/service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pierre Fabre S.A.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product/service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Piramal Pharma Solutions
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product/service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. DPT Laboratories, LTD.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product/service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. MedPharm Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product/service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Zenvisionpharma
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product/service benchmarking
      • 8.2.10.4. Strategic initiatives
Product Code: GVR-4-68040-188-4

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Topical Drugs CDMO: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 4 Global Topical Drugs: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 5 Development Stages Baseline Model Parameter Estimates, By Topical Drugs
  • Table 6 Global Topical Drugs CDMO Manufacturing Container Capacity/Batch
  • Table 7 Global Topical Drugs Capacity, by Product Type (per unit)
  • Table 8 Global Topical Drugs Capacity, by Container Type (per unit)
  • Table 9 North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
  • Table 10 List of Major Prescription Drugs, by Product Type (2022)
  • Table 11 List of Major Generic Drugs, by Product Type (2022)
  • Table 12 List of major OTC Drugs, by Product Type (2022)
  • Table 13 North America Topical Drugs CDMO market revenue estimates and forecast, by Product type, 2018 - 2030 (USD Million)
  • Table 14 North America Topical Drugs CDMO market revenue estimates and forecast, by Semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America Topical Drugs CDMO market revenue estimates and forecast, by Liquid formulations drugs, 2018 - 2030 (USD Million)
  • Table 16 North America Topical Drugs CDMO market revenue estimates and forecast, by service type, 2018 - 2030 (USD Million)
  • Table 17 North America Topical Drugs CDMO market revenue estimates and forecast, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America Topical Drugs CDMO market revenue estimates and forecast, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America Topical Drugs CDMO market revenue estimates and forecast, by sponsors, 2018 - 2030 (USD Million)
  • Table 20 North America Topical Drugs CDMO market revenue estimates and forecast, by country, 2018 - 2030 (USD Million)
  • Table 21 Company profiles: Company overview
  • Table 22 Company profiles: Financial performance
  • Table 23 Company profiles: Service benchmarking
  • Table 24 Key Company initiating service launches/upgrades
  • Table 25 Key companies initiating mergers/acquisitions/joint ventures
  • Table 26 Key companies initiating partnerships
  • Table 27 Key companies initiating expansion
  • Table 28 Key companies initiating others 

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis 
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!